⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
FRNM News
Freenome, Inc. Common stock
Form 8-K
sec.gov
FRNM
Freenome Expands Personalized Cancer Detection Portfolio, Launching SimpleScreen™ Lung Test With FDA-Approved SimpleScreen CRC Option
globenewswire.com
FRNM
Freenome to Report Third Quarter 2026 Financial Results on November 10, 2026
globenewswire.com
FRNM
Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026
globenewswire.com
FRNM
Liquid Biopsy with Emphasis on Cancer Market to Reach $8.0 Billion by 2031, Driven by Rising Cancer Incidence and Precision Medicine Adoption
globenewswire.com
GH
NTRA
EXAS
ILMN
TMO
QGEN
MYGN
PSNL
FRNM
Form 8-K/A
sec.gov
FRNM
FDA Grants Breakthrough Device Designation to Freenome’s Blood-Based SimpleScreen™ Lung Cancer Screening Test
globenewswire.com
FRNM
Form 8-K
sec.gov
PCSC
FRNM
ABT
FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
globenewswire.com
FRNM
ABT
Form 8-K
sec.gov
FRNM
PCSC